瑞舒伐他汀对早期糖尿病肾病患者肾组织血管细胞黏附分子表达的影响

目的 观察瑞舒伐他汀对早期糖尿病肾病患者肾组织血管细胞黏附分子-1(VCAM-1)表达的影响.方法 将60例早期糖尿病肾病患者按随机数字表法分为他汀组和常规组,每组30例,并以30例健康者作为对照组,他汀组在常规治疗基础上加用瑞舒伐他汀10 mg/d,疗程12周.观察三组血糖、血脂、肾功能、高敏C反应蛋白(hs-CRP)、尿微量白蛋白排泄率(UAER)及VCAM-1表达.结果 与治疗前比较,常规组治疗后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)分别为(5.83±1.02)、(3.48±0.60)、(7.12±0.99) mmol/L]无显著下降(P＞0.05),而他汀组治疗后TC、LDL-C、TG分别为(4.51±0.95)、(3.18±0.47)、(7.02±0.87) mmol/L]显著降低(P＜0.01)；治疗后常规组和他汀组UAER分别为(78.3±31.7)、(53.8±24.9)μ g/min]和hs-CRP (2.15±0.48)、( 1.59±0.55) mg/L]均明显下降(P＜0.01),且他汀组下降更明显(P＜0.05).他汀组患者肾小球细胞质中斑点状分布的VCAM-1阳性信号较常规组明显减少.结论 瑞舒伐他汀可下调肾组织VCAM-1的表达,抑制炎性反应,减少尿蛋白.

Effect of rosuvastatin on the expression of vascular cell adhesion molecule-1 of renal tissue in patients with the early-stage diabetic nephropathy

Objective To observe the effect of rosuvastatin on the expression of vascular cell adhesion molecule-1 (VCAM-1) of renal tissue in patients with the early-stage diabetic nephropathy.Methods Sixty patients with early-stage diabetic nephropathy were divided into two groups by random digits table:rosuvastatin group and regular group.The patients were given 10 mg/d rosuvastatin besides the conventional treatment in rosuvastatin group.The levels of blood glucose,blood fat,renal function,high sensitivity C-reactive protein(hs-CRP),urine albumin excretion rate(UAER) and the expression of VCAM-1 were observed.Results Compared with those before treatment,the levels of total cholesterol (TC),low density lipoprotein cholesterol (LDL-C),trtglyeride (TG) showed no decrease after treatment (5.83 ± 1.02),(3.48 ±0.60),(7.12 ±0.99) mmol/L] in regular group (P ＞0.05),but significantly decreased in rosuvastatin group (4.51 ± 0.95 ),( 3.18 ± 0.47),(7.02 ± 0.87 ) mmol/L ] (P ＜ 0.01 ).The levels of UAER and hs-CRP were significantly decreased in regular group and rosuvastatin group after treatment (78.3 ±31.7),(53.8 ± 24.9) μ g/min,and (2.15 ± 0.48),( 1.59 ± 0.55) mg/L] (P＜ 0.01 ),then rosuvastatin groupwas more conspicuous than regular group (P ＜ 0.05 ).The expression of VCAM-1 was less in rosuvastatin group than that in regular group.Conclusion Rosuvastatin can down-regulate the expression of VCAM-1 of kidney tissues in patients with the early-stage diabetic nephropathy and these indicate that rosuvastatin can reduce urine protein by inhibiting the inflammatory process.